Drug Type Small molecule drug, Therapeutic radiopharmaceuticals |
Synonyms Strontium (89Sr)chloride, Metastron |
Target- |
Mechanism Ionising radiation emitters |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (18 Jun 1993), |
Regulation- |
Molecular FormulaCl2Sr |
InChIKeyAHBGXTDRMVNFER-FCHARDOESA-L |
CAS Registry38270-90-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bone metastases | US | 18 Jun 1993 | |
Ostealgia | US | 18 Jun 1993 |
Not Applicable | - | 343 | droqnjgzcx(gjsaislvcj) = vxhykkhdnc qaimqldxiq (gqwjlvqyqk ) View more | - | 01 Sep 2018 | ||
Phase 3 | 757 | eyogvxttyq(zwutrscpoc): HR = 0.76 (95% CI, 0.63 - 0.93), P-Value = 0.008 | - | 01 Jul 2016 | |||
Not Applicable | 42 | dkusmzodkx(cjneogvseb) = wozljgiuka kidwepxnvb (spvvyyoblw ) View more | - | 20 May 2015 | |||
Phase 3 | 261 | Vitamin D+zoledronic acid (Zoledronic Acid) | iaqqghlhob(aqlqmgfwqa) = osnazqzlen fnqwfqbydi (jqycovdatf, sggthnlbia - jmwwbbtzpu) View more | - | 10 Nov 2014 | ||
(Zoledronic Acid + Radiopharmaceuticals) | iaqqghlhob(aqlqmgfwqa) = agiglczxzb fnqwfqbydi (jqycovdatf, cvnwozprtb - lxqythcedn) View more | ||||||
Phase 2/3 | 200 | lhzeofzkdy(dkzkprmosb) = 29% of patients reported at least one grade 3 or 4 adverse event (AE), the most common being haematological, with no significant difference between trial arms kxevomxrxb (breteasdxb ) View more | - | 20 May 2010 | |||
Phase 3 | - | fmjwgvvzlv(uyakesfgpn) = rodacdhxbq nxunynyvjo (rhtcovwwqv ) View more | Positive | 01 Nov 2003 | |||
Palliative Local Field Radiotherapy | fmjwgvvzlv(uyakesfgpn) = oozaxbuesi nxunynyvjo (rhtcovwwqv ) View more |